<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233570</url>
  </required_header>
  <id_info>
    <org_study_id>33000332</org_study_id>
    <nct_id>NCT01233570</nct_id>
  </id_info>
  <brief_title>Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease</brief_title>
  <official_title>Topical Tacrolimus 0.1% Ointment for Treatment of Cutaneous Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aberdeen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aberdeen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An assessment of the efficacy of topical tacrolimus in the treatment of cutaneous crohns
      disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of standardised digital photography by three independent assessors following the Physicians' Global Severity Scale before and after treatment</measure>
    <time_frame>At 12 weeks of treatment, optionally extended to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global Self Assessment</measure>
    <time_frame>12 weeks, optionally extended to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perineal Disease Activity Index</measure>
    <time_frame>12 weeks, optionally extended to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Topical tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily topical application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension</description>
    <arm_group_label>Topical tacrolimus</arm_group_label>
    <other_name>Protopic 0.1%</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  willingness and capability to follow the study procedure

          -  confirmed diagnosis of Crohn's Disease of at least 3 months duration confirmed by
             radiography, endoscopy or pathological examination

          -  required to have a skin manifestation of Crohn's disease

          -  required to give written informed consent

          -  both male and female subjects with reproductive potential required to be on an
             acceptable form of birth control for the duration of the study

          -  long-standing, concomitant immunosuppressive therapy was allowed if the dose was
             stable and not controlling the skin problem

        Exclusion Criteria:

          -  known sensitivity to tacrolimus

          -  change in aminosalicylate dosage in the four weeks prior to screening

          -  on oral steroids at over 40mg per day

          -  been commenced on methotrexate, azathoprine or ciclosporin within the last two months

          -  commenced on a a TNF-alpha monoclonal antibody within the three months prior to
             screening

          -  patients having had a stoma fashioned less than three months before enrolment

          -  patients with an immunocompromising disease

          -  patients with a diagnosis of malignancy within the last five years

          -  patients with any other condition, past or present treatment thought by the
             investigator to render the subject ineligible for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony D Ormerod, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aberdeen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Aberdeen, Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Grampian</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>November 2, 2010</last_update_submitted>
  <last_update_submitted_qc>November 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr AD Ormerod</name_title>
    <organization>University of Aberdeen</organization>
  </responsible_party>
  <keyword>Cutaneous Crohns Disease</keyword>
  <keyword>Topical Tacrolimus</keyword>
  <keyword>Protopic</keyword>
  <keyword>Metastatic Crohns Disease</keyword>
  <keyword>Pyoderma Gangrenosum</keyword>
  <keyword>Granulomatous chelitis</keyword>
  <keyword>Oral crohns disease</keyword>
  <keyword>Perianal crohns disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

